How to buy Organogenesis stock (ORGO)

Organogenesis is a drug manufacturers - specialty & generic business based in the US. Organogenesis shares (ORGO) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $3.18 – a decrease of 1.85% over the previous week. Organogenesis employs 862 staff and has a trailing 12-month revenue of around $455 million.

Our top picks for where to buy Organogenesis stock

Buy Organogenesis stock from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.

Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.

Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.

Organogenesis stock price (NASDAQ: ORGO)

Use our graph to track the performance of ORGO stocks over time.

Organogenesis shares at a glance

• Key figures

Information last updated 2024-12-18.

Latest market close	$3.18
52-week range	$2.17 - $4.71
50-day moving average more info button	$3.43
200-day moving average more info button	$2.93
Wall St. target price	$5.00
PE ratio more info button	N/A
Dividend yield more info button	N/A
Earnings per share (TTM) more info button	$-0.05

Is it a good time to buy Organogenesis stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Organogenesis price performance over time

Historical closes compared with the close of $3.18 from 2024-12-23

1 week (2024-12-18)	-1.85%
1 month (2024-11-25)	-21.29%
3 months (2024-09-25)	14.80%
6 months (2024-06-25)	27.20%

1 year (2023-12-22)	-19.70%
2 years (2022-12-23)	22.78%
3 years (2021-12-23)	10.2
5 years (2019-12-24)	5

Is Organogenesis stock undervalued or overvalued?

Valuing Organogenesis stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Organogenesis's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Organogenesis's EBITDA

Organogenesis's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $28.7 million.

The EBITDA is a measure of a Organogenesis's overall financial performance and is widely used to measure a its profitability.

Organogenesis financials

Revenue TTM	$455 million
Operating margin TTM	5.42%
Gross profit TTM	$345.9 million
Return on assets TTM	1.64%
Return on equity TTM	-2.66%
Profit margin	-1.62%
Book value	$2.10
Market Capitalization more info button	$429.5 million

TTM: trailing 12 months

Organogenesis share dividends

We're not expecting Organogenesis to pay a dividend over the next 12 months.

Organogenesis share price volatility

Over the last 12 months, Organogenesis's shares have ranged in value from as little as $2.165 up to $4.705. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Organogenesis's is 1.598. This would suggest that Organogenesis's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Organogenesis overview

Organogenesis Holdings Inc. , a regenerative medicine company, develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Novachor, a chorion membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, cytokines, and growth factors; NuShield, dehydrated placental tissue covering amnion and chorion membranes for spongy/intermediate layer intact; and PuraPly AM, an antimicrobial barrier that enables conformability and fluid drainage. Its products also include FortiShield, a biosynthetic wound matrix for use as a temporary protective covering; PuraPly MZ, a micronized particulate version of PuraPly for the management of open wounds in the surgical setting; and CYGNUS Dual, a dehydrated placental tissue preserved to retain the ECM scaffold. The company's pipeline products include ReNu, a cryopreserved suspension used to support healing of soft tissues; PuraForce, a bioengineered porcine collagen surgical matrix for use in soft tissue reinforcement applications; and TransCyte, a bioengineered tissue for the treatment of partial thickness burns. It serves hospitals, wound care centers, government facilities, ambulatory service centers, and physician office through direct sales representives and independent agencies. Organogenesis Holdings Inc.

Frequently asked questions

What percentage of Organogenesis is owned by insiders or institutions?
Currently 43.96% of Organogenesis shares are held by insiders and 48.253% by institutions. How many people work for Organogenesis?
Latest data suggests 862 work at Organogenesis. When does the fiscal year end for Organogenesis?
Organogenesis's fiscal year ends in December. Where is Organogenesis based?
Organogenesis's address is: 85 Dan Road, Canton, MA, United States, 02021 What is Organogenesis's ISIN number?
Organogenesis's international securities identification number is: US68621F1021 What is Organogenesis's CUSIP number?
Organogenesis's Committee on Uniform Securities Identification Procedures number is: 68621F102